Xu J - Search Results

1

Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial.

Xu J, Wang Y, Jiang C, Cao H, Jiang J, Xu B, Sun T. Xu J, et al. Among authors: xu b. Front Oncol. 2020 Oct 9;10:524223. doi: 10.3389/fonc.2020.524223. eCollection 2020. Front Oncol. 2020. PMID: 33163394 Free PMC article.

2

Correlation between hormone receptor status and depressive symptoms in patients with metastatic breast cancer.

Guo X, Xu J, Ying E, Yu Z, Sun T. Guo X, et al. Among authors: xu j. Oncotarget. 2017 Feb 2;8(31):50774-50781. doi: 10.18632/oncotarget.15037. eCollection 2017 Aug 1. Oncotarget. 2017. PMID: 28881602 Free PMC article.

3

Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.

Xu J, Sun T, Guo X, Wang Y, Jing M. Xu J, et al. Oncol Lett. 2018 Mar;15(3):2855-2862. doi: 10.3892/ol.2017.7637. Epub 2017 Dec 19. Oncol Lett. 2018. PMID: 29456719 Free PMC article.

4

Predictive Value of CD4⁺/CD8⁺ Ratio in Patients with Breast Cancer Receiving Recombinant Human Thrombopoietin.

Xu J, Jiang L, Cao H, Jia Y, Wu S, Jiang C, Sun T. Xu J, et al. J Interferon Cytokine Res. 2018 May;38(5):213-220. doi: 10.1089/jir.2017.0146. Epub 2018 Apr 17. J Interferon Cytokine Res. 2018. PMID: 29664688

5

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67.

Xu J, Guo X, Jing M, Sun T. Xu J, et al. Onco Targets Ther. 2018 Apr 19;11:2269-2275. doi: 10.2147/OTT.S159830. eCollection 2018. Onco Targets Ther. 2018. PMID: 29719409 Free PMC article.

6

Glycogenolysis in Acquired Glioma Resistance to Temozolomide: A Role for the [Ca²⁺]_i-dependent Activation of Na,K-ATPase/ERK_1/2 Signaling.

Xu J, Zhang Y, Guo X, Sun T. Xu J, et al. Front Pharmacol. 2018 Aug 7;9:873. doi: 10.3389/fphar.2018.00873. eCollection 2018. Front Pharmacol. 2018. PMID: 30131700 Free PMC article.

7

Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer.

Yang J, Xu J, E Y, Sun T. Yang J, et al. Among authors: xu j. Cancer Med. 2019 Feb;8(2):492-500. doi: 10.1002/cam4.1891. Epub 2019 Jan 10. Cancer Med. 2019. PMID: 30632318 Free PMC article.

8

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.

Xu J, Bao H, Wu X, Wang X, Shao YW, Sun T. Xu J, et al. Oncol Lett. 2019 Jul;18(1):449-455. doi: 10.3892/ol.2019.10287. Epub 2019 Apr 30. Oncol Lett. 2019. PMID: 31289516 Free PMC article.

9

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies.

Niu Y, Xu J, Sun T. Niu Y, et al. Among authors: xu j. J Cancer. 2019 Aug 29;10(22):5504-5517. doi: 10.7150/jca.32628. eCollection 2019. J Cancer. 2019. PMID: 31632494 Free PMC article.

10

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.

Wu S, Zhang L, Li H, Xu J, Jiang C, Sun T. Wu S, et al. Among authors: xu j. Trials. 2020 May 24;21(1):420. doi: 10.1186/s13063-020-04342-x. Trials. 2020. PMID: 32448335 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,212 results

Search Page

Filters